ADAPTIVE AND INNATE IMMUNE RESPONSES
TRIGGERED TO NEUTRALIZE GASTRIN HORMONES
AS A THERAPY FOR GI CANCERS

NEWS FLASH

3 November 2017: 

TYG oncology revealed today that last November, Cancer Research UK and Cancer Research Technology (CRT), the charity’s commercial arm, have signed an agreement with TYG oncology Ltd (TYG) to take its new antigen-specific, active checkpoint control cancer vaccine TYG100, into clinical trials in cancer patients with advanced solid tumours. 
http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-11-04-cancer-research-uk-and-cancer-research-technology-partner-with-tyg-oncology-to-develop-next

Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “It’s a very promising area of research and we’re excited to be working with TYG oncology to take this to the next stage.  TYG100 is among a range of new treatments that use a patient’s own immune system to target hormones that encourage the growth and spread of solid tumours. It works by triggering the production of antibodies that specifically target two members of the gastrin hormone family* that help to fuel tumour growth.

Under the agreement, Cancer Research UK and TYG will share the cost of the process development and production of TYG100 for the clinic.  Cancer Research UK’s Centre for Drug Development (CDD) will then sponsor and manage a Phase I clinical trial of TYG100 in cancer patients with advanced solid tumours, mainly to evaluate drug safety and toxicity. It will take place across the Experimental Cancer Medicine Centres network, a nationwide initiative funded by Cancer Research UK and the UK’s four Health Departments.  The collaboration forms part of Cancer Research UK’s Clinical Development Partnership (CPD) scheme, meaning that at the end of the trial, TYG oncology has the option of either retaining rights to the new treatment or transferring them to Cancer Research UK to continue development through a new partner.

Fred Jacobs, CEO of TYG oncology, said: “We are very pleased to be working in partnership with the clinical experience and expertise from Cancer Research UK to advance TYG100. Cancer Research UK’s sponsorship of the Phase I clinical trial is a significant technical and financial validation of our novel therapeutic vaccine. TYG100 will be attacking some of the most difficult and deadliest solid tumours, including pancreatic and gastro-oesophageal cancers.”

Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “We hope that next generation cancer vaccines like this one will build on the widespread success of existing hormonal treatments – such as those targeting oestrogen in breast cancer and testosterone in prostate cancer. It’s a very promising area of research and we’re excited to be working with TYG oncology to take this to the next stage. Our Clinical Development Partnerships are a novel approach that allows companies to benefit from Cancer Research UK’s extensive drug development resources in a way that is mutually beneficial and that ultimately helps new treatments reach patients more quickly.”

Fred Jacobs said, “With the Charity leading the TYG100 efforts the company is able to focus on the further development of a series of therapeutics to replace monoclonal antibodies.” 

“To prove our superiority to monoclonals, we have decided to tackle Her2/neu as our next project, imaginatively named TYG200. TYG200 has already been tested in primates and induces polyclonal antibodies similar to Herceptin and Perjeta as well as polyclonal Her2 specific cellular immune responses. Importantly, these include activation of Her2 specific cytotoxic T cells with the antibodies and T cells working together in attacking the tumour. After Her2/neu, we intend to go after every major monoclonal on the market. We have some other programs in the works for infectious diseases linked to cancers like Epstein-Barr Virus and Human Papilloma Virus. Our drugs are very well tolerated, inexpensive to manufacture and inexpensive to administer. TYG products may be used in combination with most existing therapies.”

Fred added that, "We have the hottest technology in oncology with independent validation of our science by Cancer Research UK, a great collaborator to partner with. TYG100 is only the 18th funded project out of over 350 reviewed since 2008 and these projects have a very high success rate, further de-risking an investment in TYG. This is important as we’ll need additional investment to develop all these assets simultaneously.”



March 2016: OncoQR and TYG oncology Ltd announce the expansion of their collaboration agreement to tackle additional cancers. http://tinyurl.com/zcyzelp

March 2016: OncoQR announces the preclinical dose-ranging findings for TYG100. A single dose achieved clinical levels of antibodies in NHP including patients treated concurrently with gemcitabine. 
http://tinyurl.com/jptsq4z

February 2016:  Experimental Cancer Medicines Centres in Leeds, Glasgow and Belfast design parallel first-in-human trials in pancreatic and gastroesophageal cancers for TYG100.

November 2014: TYG oncology files for patent protection of TYG100.

April 2014: on behalf of TYG, Dr. Paul Broome presented the TYG100 technology at the annual AACR meeting. Historically clinically relevant titres of gastrin neutralising antibodies obtained in earlier Phase 3 trials were exceeded >100 fold with TYG100 with no serious adverse events.

March 2014:  DANIEL D. VON HOFF, M.D., F.A.C.P., a world renowned expert in the field of pancreatic advises the company on critical Phase 2 trial design.

March 2014:  GRAHAM DOCKRAY, Emeritus Professor of Physiology at the University of Liverpool, is welcomed as a new member of it's scientific advisory board January 2013: TYG oncology Ltd registered - Companies House, UK. 

[Sleeker_special_clear]